Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET

Company Participants

Sherry Aulin - Chief Financial Officer

Ian Mortimer - President and Chief Executive Officer

Chris Kenney - Chief Medical Officer

Chris Von Seggern - Chief Commercial Officer

Conference Call Participants

Brian Abrahams - RBC Capital Markets

Tessa Romero - JPMorgan

Marc Goodman - SVB

Andrew Tsai - Jefferies

David Hoang - SMBC

Lachlan Hanbury - William Blair

Operator

Good afternoon and welcome to the Xenon Pharmaceuticals Reports Second Quarter Results Conference Call. [Operator Instructions] Thank you. Sherry Aulin, Chief Financial Officer, you may begin your conference.

Sherry Aulin

Thank you. Good afternoon, everyone. Thank you for joining us on our call and webcast to discuss Xenon’s second quarter 2022 financial and operating results. Joining me are Ian Mortimer, Xenon’s President and Chief Executive Officer; Dr. Chris Kenney, Xenon’s Chief Medical Officer; and Dr. Chris Von Seggern, Xenon’s Chief Commercial Officer.

Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding our and our collaborators’ development plans; anticipated regulatory interactions and submissions; anticipated results and related timelines; the potential efficacy, safety profile, addressable market and commercial potential of our proprietary and partnered product candidates; the efficacy of our clinical trial designs and anticipated enrollment; the potential receipt of milestone payments and royalties from our collaborators; our expectation of having sufficient cash to fund operations into 2026; and the timing of potential release of future clinical data.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control including the risks and uncertainties described from time-to-time in our SEC filings. Our results may differ materially from those projected on today’s call. We undertake no obligation to publicly update any forward-looking statement. Today’s press release summarizing Xenon’s second quarter 2022 financial results and the accompanying quarterly report on Form 10-Q will be made available under the Investors section of our website at www.xenon-pharma.com and filed with the SEC and on SEDAR.

Now, I would like to turn the call over to Ian.

Ian Mortimer

Thanks, Sherry. Good afternoon, everyone and thanks for joining our call. I will start today’s call with a high level summary of our recent progress. I will then turn the call over to Chris Kenney who will provide additional color around our XEN1101 end of Phase 2 meeting with the FDA and our next steps within our Phase 3 program, including our expansion into the additional epilepsy indication of primary generalized tonic-clonic seizures, or PGTCS. Chris will also provide his perspective on the additional X-TOLE data which we recently released. Chris Von Seggern will then share some market research insights shaping our clinical plans in PGTCS and the commercial opportunity for developing XEN1101 within this indication, where there remains a significant unmet medical need. Sherry will conclude our call by briefly summarizing our partner programs, financial results and events ahead. We look forward to taking your questions during the Q&A session at the end of the call.